Becton, Dickinson and Company (NYSE:BDX) shares acquired by New York Life Investment Management LLC

New York Life Investment Management LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 0.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,826 shares of the medical instruments supplier’s stock after acquiring an additional 222 shares during the period. New York Life Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $9,308,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ontario Teachers Pension Plan Board boosted its stake in Becton, Dickinson and Company by 3.8% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock, valued at $451,641,000 after acquiring an additional 68,509 shares in the last quarter. Jennison Associates LLC boosted its stake in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after acquiring an additional 18,786 shares during the last quarter. Norden Group LLC boosted its stake in Becton, Dickinson and Company by 2,086.7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $11,998,000. Finally, Avity Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after acquiring an additional 5,527 shares in the last quarter. 86.97% of the shares are held by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

BDX opened at $232.67 on Friday. The stock has a market cap of $67.24 billion, a P/E ratio of 51.25, a P/E/G ratio of 1.98 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85, and a quick ratio of 1.36. The stock’s 50-day simple moving average is $234.06, and its 200-day simple moving average is $235.93. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX – Get Your Free Report ) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. In the same quarter last year, the firm earned $2.96 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company announces dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a dividend of $0.95 per share. This represents a dividend of $3.80 on an annualized basis and a yield of 1.63%. The ex-dividend date of this dividend is Monday, September 9. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

The Wall Street analyst weighs in

BDX has been the subject of several recent analyst reports. Raymond James decreased their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Evercore ISI decreased their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Citigroup decreased their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, the 26th July. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus price target of $279.50, according to MarketBeat.com.

Check out our latest report on BDX

Insiders place their bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Corporate insiders own 0.31% of the company’s shares.

Becton, Dickinson and Company Company Profile

(Free report)

Becton, Dickinson and Company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences and BD Interventional.

Read more

Want to see what other hedge funds own BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Get news and reviews for Becton Dickinson and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson & Company and related companies with MarketBeat.com’s FREE daily email newsletter.